Fundraising Fox
Serina Therapeutics
NYSE: SERHuntsville, US · Alabama corporation · 1 known investors
Find your way into Serina Therapeutics
Each arrow is one introduction. Sign up to fill in the first one.
154 people can intro you to Tacey
Ask Purnanand Sarma to introduce you to Tacey Viegas
You →Purnanand · together at Nektar Therapeutics →Tacey
Sign up to find every way you can get introduced to Serina Therapeutics
- Your email: who you already know at Serina Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Serina Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Serina Therapeutics is a clinical-stage biotechnology company developing its POZ Platform, a polymer technology ("POZylation") that modifies proven small molecule drugs to enable controlled, sustained release with fewer side effects. Its lead candidate, SER-252 (POZ-apomorphine), targets advanced Parkinson's disease, and the platform is also applied to CNS indications and RNA medicines.
Founders & leadership
JM
J Milton HarrisFounder
RW
Randall W MoreadithExecutive
TV
Tacey ViegasExecutiveTacey Viegas has over 30 years of experience in drug discovery, development, and delivery across oncology, pain, neurology, immunology, antivirals, and dermatology, with leadership roles in chemistry, manufacturing, controls, preclinical biology, and early-stage clinical development.
SL
Steven LedgerChief Executive Officer
MD
Michael D BentleyNamed on SEC filing
Board
MA
Miguel A LoyaBoard director
JR
James R Hudson, Jr.Board director
BF
Barbara FiskBoard director
Investors · 1
Funding
SEC filings, press & company announcements$31.4M disclosed across 6 of 7 rounds · 2014–2026
- Undisclosed amountprivate placementMar 2026Source ↗
▶$10MraisedMar 2023 · 1 investors · BiotechnologyRule 506(b)
▶$10MraisedMar 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Barbara M FiskDirector
- James R Hudson, Jr.Director
- Randall W MoreadithExecutive Officer, Director
- Steve LedgerDirector
- Greg H Bailey, M.D.Director
- J Milton HarrisExecutive Officer, Director
- Tacey ViegasExecutive Officer
- Michael D BentleyExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Mar 2023
- Incorporated
- Corporation, Alabama
- Federal exemptions
- 06b
▶$3.6MraisedNov 2022 · 1 investors · BiotechnologyRule 506(b)
▶$3.6MraisedNov 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Miguel A LoyaDirector
- Randall W MoreadithExecutive Officer, Director
- James R Hudson, Jr.Director
- Michael D BentleyExecutive Officer, Director
- J Milton HarrisExecutive Officer, Director
- Barbara FiskDirector
- Tacey ViegasExecutive Officer
- Offering amount
- $3.6M
- Amount sold
- $3.6M
- First sale
- Nov 2022
- Incorporated
- Corporation, Alabama
- Federal exemptions
- 06b
▶$1MraisedJul 2022 · 3 investors · BiotechnologyRule 506(b)
▶$1MraisedJul 2022 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Barbara FiskDirector
- Miguel A LoyaDirector
- James R Hudson, Jr.Director
- Randall W MoreadithExecutive Officer, Director
- Tacey ViegasExecutive Officer
- Michael D BentleyExecutive Officer, Director
- J Milton HarrisExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $1M
- First sale
- Jun 2022
- Incorporated
- Corporation, Alabama
- Federal exemptions
- 06b
▶$3.7MraisedJun 2021 · 12 investors · BiotechnologyRule 506(b)
▶$3.7MraisedJun 2021 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael D BentleyExecutive Officer, Director
- James R Hudson, Jr.Director
- Randall W MoreadithExecutive Officer, Director
- J Milton HarrisExecutive Officer, Director
- Barbara FiskDirector
- Miguel A LoyaDirector
- Tacey ViegasExecutive Officer
- Offering amount
- $76.2M
- Amount sold
- $3.7M
- First sale
- Jul 2019
- Incorporated
- Corporation, Alabama
- Federal exemptions
- 06b
▶$8.2MraisedApr 2018 · 18 investors · BiotechnologyRule 506(b)
▶$8.2MraisedApr 2018 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James R Hudson, Jr.Director
- Michael D BentleyExecutive Officer, Director
- Barbara FiskDirector
- J Milton HarrisExecutive Officer, Director
- Miguel A LoyaDirector
- Tacey ViegasExecutive Officer
- Randall W MoreadithExecutive Officer, Director
- Brendan RaeExecutive Officer
- Offering amount
- $32.5M
- Amount sold
- $8.2M
- First sale
- Jan 2017
- Incorporated
- Corporation, Alabama
- Federal exemptions
- 06b
▶$4.9MraisedMar 2015 · 21 investors · BiotechnologyRule 506(b)
▶$4.9MraisedMar 2015 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tacey ViegasExecutive Officer
- J Milton HarrisExecutive Officer, Director
- James R Hudson, Jr.Director
- Randall W MoreadithExecutive Officer, Director
- Barbara FiskDirector
- Michael D BentleyExecutive Officer, Director
- Offering amount
- $6.3M
- Amount sold
- $4.9M
- First sale
- Apr 2014
- Incorporated
- Corporation, Alabama
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 7
Sionna TherapeuticsSionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs. It is advancing a portfolio of NBD1 stabilizers and complementary CFTR modulators intended to be used in combination to normalize CFTR function in CF patients.
Serna BioSerna builds a platform to unlock the transcriptome as a drug target for drug discovery. The company integrates technology and biology to change drug discovery processes.
Day One BiopharmaceuticalsDay One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.
Switch TherapeuticsSwitch Therapeutics develops RNA interference (RNAi) therapeutic applications targeting central nervous system diseases, leveraging research from Caltech, Harvard Medical School, and City of Hope.
Silence TherapeuticsSilence Therapeutics is a biotechnology company that discovers and develops short interfering RNA (siRNA) molecules designed to reduce the production of disease-associated proteins through the natural mechanism of RNA interference, with its proprietary mRNAi GOLD platform targeting specific genes in the liver for rare and common diseases.
Neurona TherapeuticsNeurona Therapeutics is a clinical-stage biotherapeutics company developing allogeneic neural cell therapies to treat chronic disorders of the nervous system. Founded by neuroscientists and stem cell researchers from UC San Francisco, it operates a regenerative medicine discovery platform and manufactures neuronal, glial, and gene-edited cell therapy candidates in its own cGMP facility.
Syrna TherapeuticsSyrna Therapeutics is a biotech company developing small-molecule covalent translation inhibitors that bind and modify structured domains in the mRNA of disease-causing proteins to block their expression. It uses a 3D structure-guided drug discovery platform, with lead programs in immunology and neurodegeneration and a broader pipeline spanning metabolic disease and oncology.
Companies working in the same space as Serina Therapeutics.
Frequently asked questions
- What does Serina Therapeutics do?
- Serina Therapeutics is a clinical-stage biotechnology company developing its POZ Platform, a polymer technology ("POZylation") that modifies proven small molecule drugs to enable controlled, sustained release with fewer side effects. Its lead candidate, SER-252 (POZ-apomorphine), targets advanced Parkinson's disease, and the platform is also applied to CNS indications and RNA medicines.
- Who founded Serina Therapeutics?
- Serina Therapeutics was founded by J Milton Harris.
- Who are Serina Therapeutics's investors?
- Serina Therapeutics's investors include New Capital Partners.
- How much funding has Serina Therapeutics raised?
- Serina Therapeutics has disclosed $31.4M raised across 6 of its 7 known rounds.
- Where is Serina Therapeutics headquartered?
- Serina Therapeutics is headquartered in Huntsville, US.